Hariharan Ananthakrishnan

Hariharan Ananthakrishnan is a Principal Software Engineer at Tweets are my own views.

[Hariharan Ananthakrishnan @hariscorner]

Hyper Scale VPC Flow Logs enrichment to provide Network Insight https://t.co/yHDIpCLaoq
#cloudnetworking #cloudinfrastructure #DataAnalytics #BigData

[ArteraAI @arteraAI]

At #ASTRO26, our collaborators will share findings spanning biomarker validation, treatment selection, algorithmic fairness, risk prediction and more. Be sure to mark your calendar!

See the lineup below for some of our presentations:

#ArteraAI

[ArteraAI @arteraAI]

Next up for Artera: two opportunities to connect with the #ProstateCancer community.

📍 @MayoClinic's Radiation Oncology Education for NPs & PAs
📍 Reed M. Nesbit Urologic Society Meeting

Looking forward to a great week of learning and collaboration!

#Urology #ArteraOnTheGo

[ArteraAI @arteraAI]

How is AI transforming cancer treatment?

Listen to the conversation on how AI-powered tools are helping personalize care for patients: https://t.co/rL56WHPCuf

#AIinHealthcare #ProstateCancer #PrecisionMedicine #ArteraAI

[ArteraAI @arteraAI]

Prostate cancer affects everyone differently. AI can help doctors spot patterns in biopsy images to guide decisions, like whether short-term ADT with radiation may help. Because cancer is personal, therapy should be too.

Learn more in this summary of our predictive validation:

[ArteraAI @arteraAI]

ICYMI: Prof. Nick James of @ICR_London joined The @Uromigos Podcast to share new #ASCO25 data on the ArteraAI Prostate Test—showing how AI can identify which high-risk patients truly benefit from adding abiraterone to ADT: https://t.co/b3J7QcI4iC

[ArteraAI @arteraAI]

We’re proud to wear blue in support of #MensHealthWeek and #WearBlueDay.

With prostate cancer ranking as the second most common cancer in U.S. men according to @AmericanCancer, it’s a powerful reminder of the value of early detection, awareness, and personalized care.

[ArteraAI @arteraAI]

Just announced at #ASCO25: The ArteraAI Prostate Test is now enhanced for high-risk localized prostate cancer—helping identify which patients benefit from abiraterone and who may safely avoid added toxicity, cost, and complexity: https://t.co/Oj9ixWlVpU

[ArteraAI @arteraAI]

We’re proud to have @Benioff on Artera’s board, helping shape how AI transforms precision medicine.

Check out his latest interview on the future of AI in business via @ChiefExecGrp: https://t.co/bMeuMuj9ru

#AIinHealthcare #MarcBenioff #Leadership

[ArteraAI @arteraAI]

It's not easy to deploy clinical #AImodels globally, due to regulatory & compliance issues.

In this #techblog, we explain our 4-step process for international deployment and how we partnered with @union_ai as we expanded into Australia.

https://t.co/7xXkMq23Zd

[ArteraAI @arteraAI]

That’s a wrap on @ASCO #GU25! 🎉 The #ArteraAI team had an incredible time connecting with colleagues, sharing insights, and advancing the conversation around #precisionmedicine in #prostatecancer.

[ArteraAI @arteraAI]

We're excited to attend the @MayoClinic Urology Review in Puerto Rico this month! Stop by to meet with #ArteraAI's Paul Hawkinson and John Benton to learn more about how the ArteraAI Prostate Test is helping patients with #prostatecancer. https://t.co/ETySYUy6rF

[ArteraAI @arteraAI]

The #ArteraAI team had a great time at the @GRUrology #IPCU2025 event in Colorado, where leading experts gathered to discuss the latest advancements and best practices in the prevention and treatment of #prostatecancer.

[ArteraAI @arteraAI]

We're excited to collaborate with @TempusAI and increase access to the #ArteraAI Prostate Test. It's an honor to be selected by a pioneer in #precisionmedicine to be their exclusive provider of #digitalpathology tests for #prostatecancer.

To learn more:
https://t.co/QtxzkxAfmD

[ArteraAI @arteraAI]

In @JCOPO_ASCO, Dr. Jonathan Tward et al. highlight how #ArteraAI’s multimodal #AI models reclassify risk categories, improving accuracy over current #NCCN methods - an approach that supports better decision-making and personalized care: https://t.co/fxeded6aWu

[Nathan Silberman @NCSilberman]

Progress developing pathology foundation models has been incredible. Luminaries like @AI4Pathology
@naotous @richardjchen @nfusi @ntenenz, @GreatAndrew90, @rahulgk, Alexandre Filiot, Eric Zimmermann, Tong Ding, and many others have advanced the state-of-the-art rapidly.

[ArteraAI @arteraAI]

It's time for another tech blog!

Learn more about the behind-the-scenes work of Artera engineer, Sufiyan Ghori, how he deals with network conflicts and some best practices to follow to avoid them in the first place.

https://t.co/PycxecR8Nt

#AWS #GitHub #AIinfrastructure

[ArteraAI @arteraAI]

The Artera team had a great time at #ASTRO2024!

We met with a ton of folks, discussing the science behind the #ArteraAI Prostate Test, and presenting new research on how AI can inform treatment decisions for omCSPC - an early stage of metastatic #prostatecancer.

[ArteraAI @arteraAI]

Hola, Dominican Republic!

@AndreEsteva and Peter Wood from #ArteraAI will be joining CorePlus and meeting with @CAU_URO. We are excited to share how our #MMAI platform is impacting #prostatecancer treatment decision making.

[ArteraAI @arteraAI]

Artera is excited to participate in #ASTRO24!

Don't miss the oral presentations from Yang Song of @UMBaltimore and Philip Sutera of @JohnsHopkins, Oct 2 at 8:00 AM and 8:10 AM ET!

#ArteraOnTheGo #CancerTreatment #ProstateCancer

[ArteraAI @arteraAI]

#ArteraAI is honored to be named a Finalist in the 2024 @DigiHlthHubFdn Awards! We've been selected for Best AI Healthcare Win, from among thousands of submissions globally. We are proud to be advancing innovation in healthcare!